Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06754540 | Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention. | not yet recruiting | Phase 2 | 51 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jan 17, 2025 | clinicaltrials |
| NCT06777264 | Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1(JUVENTAS-ALL05) | not yet recruiting | Phase 2 | 20 | First Affiliated Hospital of Zhejiang University |
| 0 |
| Jan 15, 2025 |
| clinicaltrials |
| NCT05281809 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 30 | John ListerOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05885464 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | active not recruiting | Phase 1 / Phase 2 | 5 | Beam Therapeutics Inc.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06179524 | CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL | recruiting | Phase 2 | 100 | Beijing Yongtai Ruike Biotechnology Company LtdINDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05528939 | Feasibility/Acceptability of Attentional-Control Training in Survivors(FAACTS) | recruiting | N/A | 50 | Children's National Research InstituteOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06765915 | Avapritinib Maintenance for AML With KIT Mutations | not yet recruiting | Phase 2 | 47 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06765928 | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT | not yet recruiting | Phase 2 | 73 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06764589 | Liquid Micro-biopsy: a Novel Approach to Study Tumor Microenvironment From the Peripheral Blood | active not recruiting | — | 90 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06760260 | Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 7 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06762132 | A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04476199 | Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT | active not recruiting | Phase 2 | 100 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06758726 | Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML | not yet recruiting | N/A | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 6, 2025 | clinicaltrials |
| NCT06756152 | Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis | recruiting | Phase 2 / Phase 3 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06752785 | CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. | recruiting | Phase 1 | 10 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06643195 | Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia | not yet recruiting | N/A | 358 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04623944 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | active not recruiting | Phase 1 | 61 | Nkarta, Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06741722 | Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML | recruiting | Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746519 | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 135 | Chen SuningOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06746571 | Role of Cbc Indices in Acute Lymphoblastic Leukemia Patients | not yet recruiting | N/A | 100 | Sohag UniversityOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05477589 | Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML(SCRIPT-AML) | recruiting | Phase 3 | 170 | Vastra Gotaland RegionOTHER_GOV | 10 | Dec 19, 2024 | clinicaltrials |
| NCT03595787 | COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome(COHABILIT) | active not recruiting | N/A | 50 | Institut Paoli-CalmettesOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04027309 | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy(HOVON 156 AML) | active not recruiting | Phase 3 | 777 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 13 | Dec 17, 2024 | clinicaltrials |
| NCT06731699 | A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS | recruiting | Phase 1 | 72 | Chengdu FenDi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06101381 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma(CARTHEDRALL) | recruiting | Phase 1 / Phase 2 | 81 | University of Sao PauloOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06722638 | Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia(VIRALL) | recruiting | N/A | 40 | Children's National Research InstituteOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06723496 | Psychiatric Problems in Children With Acute Lymphoblastic Leukemia and Their Caregivers | active not recruiting | — | 90 | Assiut UniversityOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | recruiting | Phase 1 | 54 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Dec 6, 2024 | clinicaltrials |
| NCT06721598 | An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders | not yet recruiting | — | 60 | National Research Center for Hematology, RussiaNETWORK | 1 | Dec 6, 2024 | clinicaltrials |
| NCT05212103 | PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9(CANSI) | enrolling by invitation | — | 30 | Turku University HospitalOTHER_GOV | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03356262 | The QUebec Adipose and Lifestyle InvesTigation in Youth (QUALITY) Cohort(QUALITY) | active not recruiting | — | 630 | St. Justine's HospitalOTHER | 0 | Dec 2, 2024 | clinicaltrials |
| NCT06711679 | Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia | enrolling by invitation | Phase 4 | 180 | Yilin ZhaoOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06702566 | The Effect of Serum Ferritin in irAE | recruiting | N/A | 1,500 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06702098 | Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia(iNK-r/r AML) | not yet recruiting | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03155191 | Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia(TBI-1501) | active not recruiting | Phase 1 / Phase 2 | 21 | Takara Bio Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05509855 | A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 | enrolling by invitation | — | 44 | Allotera TherapeuticsINDUSTRY | 2 | Nov 20, 2024 | clinicaltrials |
| NCT06696833 | Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia | recruiting | Early Phase 1 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06393985 | Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06034275 | Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies | recruiting | Phase 1 | 36 | Vincerx Pharma, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06420063 | Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML(BAH244) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06420076 | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells(BAH246) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03927261 | PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS | active not recruiting | Phase 1 | 88 | Precigen, IncINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04168502 | Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML | recruiting | Phase 3 | 414 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04763928 | Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax(ENABLE) | active not recruiting | Phase 2 | 101 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06024031 | NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After Chemotherapy | active not recruiting | Phase 2 | 30 | Peking University People's HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06678282 | JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Shenzhen Genocury Biotech Co., Ltd.INDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06073769 | A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia | recruiting | — | 154 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05703126 | Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML | recruiting | N/A | 100 | Samara State Medical UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06608732 | Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06674850 | Systemic Inflammation Response Index and C-Reactive Protein to Albumin Ratio in Acute Lymphoblastic Leukemia | not yet recruiting | — | 36 | Assiut UniversityOTHER | 0 | Nov 5, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 17, 2025source: clinicaltrials